XENCOR Maintains Buy Rating -- Price Target Lowered to $27.00 by Truist Securities
Truist Securities maintained a Buy rating for Xencor (XNCR) but lowered its price target from $29.00 to $27.00, reflecting cautious optimism. Despite the maintained rating, GuruFocus indicates that Xencor is significantly overvalued by 56.2%, trading at $14.89 against a GF Value™ of $9.53, and has an average GF Score™ of 52/100, with concerns in profitability and growth. Insider activity also shows sales totaling $422,138 with no purchases in the last three months, suggesting potential caution for investors.
XNCR - Xencor Inc Revenue Breakdown
This article provides a financial breakdown of Xencor Inc (XNCR), detailing key financial metrics such as market capitalization, revenue, income, sales, and various ratios. It includes per-share data, growth rates, insider and institutional ownership, and stock performance over different periods. The data indicates mixed financial performance with significant insider and institutional ownership.
Price to earnings forward of Xencor, Inc. – NASDAQ:XNCR
This page provides information on the forward price-to-earnings ratio for Xencor, Inc. (NASDAQ: XNCR). It is a financial data point presented within the context of TradingView's platform, offering financial information for various market instruments. The content is primarily navigational and informational regarding Xencor's financial metrics.
Price to sales forward of Xencor, Inc. – TRADEGATE:XE9
This article provides financial information for Xencor, Inc. (TRADEGATE:XE9), specifically focusing on its price-to-sales forward metric. It details that while the market is currently closed with no trades, financial data and analysis are available, supplied by various financial services like ICE Data Services and FactSet.
Enterprise value to revenue forward of Xencor, Inc. – NASDAQ:XNCR
This article provides a financial snapshot for Xencor, Inc. (NASDAQ: XNCR) focusing on its enterprise value to revenue. It indicates that the content is primarily data-driven, likely showing financial metrics for the company. The main source appears to be TradingView, offering an overview of Xencor's financial health, news, and market performance.
Liquidity Mapping Around (XNCR) Price Events
Xencor Inc. (NASDAQ: XNCR) shows strong sentiment across all horizons, supporting an overweight bias according to AI models. The analysis identifies a mid-channel oscillation pattern and offers an exceptional 65.6:1 risk-reward short setup. Three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are provided, tailored to different risk profiles and holding periods, alongside multi-timeframe signal analysis.
XE9 Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Xencor, Inc. (XE9) stock, based on analyst opinions. It includes future price estimates, details on past earnings and revenue, and key financial metrics like EBITDA. The article also covers frequently asked questions about XE9's stock ticker, reports, next earnings date, and employee count.
Xencor, Inc. Actuals & Estimates (FWB:XE9)
This article provides an overview of Xencor, Inc. (FWB:XE9) financial actuals and estimates, including its stock ticker, forecast, historical prices, and dividend policy. It details the company's past earnings and revenue figures, as well as estimates for upcoming quarters, and notes its employee count and EBITDA performance. The piece also includes a disclaimer that the information provided is not investment advice.
XE9 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Xencor, Inc. (XE9) stock, including its price target and analyst ratings. It also offers key financial data such as historical earnings, estimated revenues, net income, and EBITDA, along with information on its employees and dividend policy. The report emphasizes that the content is not investment advice and encourages readers to conduct their own research.
XNCR Forecast — Price Target — Prediction for 2027
This article provides a forecast for Xencor, Inc. (XNCR) stock, including analyst price targets, current stock performance, and key financial data. It highlights that analysts have a maximum price estimate of $43.00 and a minimum of $14.00, with the stock recently increasing by 2.63% in 24 hours. The report also details historical highs and lows, market capitalization, and upcoming earnings dates.
Xencor, Inc. Actuals & Estimates (NASDAQ:XNCR)
This article provides key financial data and analyst estimates for Xencor, Inc. (NASDAQ: XNCR), including its current stock price, historical performance, analyst price targets, and upcoming earnings report. It covers various financial metrics such as revenue, net income, and market capitalization, along with insights into the company's volatility and employee count. The content is presented in a Q&A format, offering a comprehensive overview for potential investors.
Price to book forward of Xencor, Inc. – NASDAQ:XNCR
This article displays the "Price to book forward" financial metric for Xencor, Inc. (NASDAQ: XNCR) as presented on TradingView. It provides a snapshot of this specific financial data point for the biotechnology company. The content appears to be a stub or a data-focused page from a financial platform.
Xencor director Ellen Feigal sells $89,369 in company stock By Investing.com
Xencor director Ellen Feigal sold 6,843 shares of the company's common stock for $89,369 on June 18, 2026, through a pre-arranged trading plan. Following the sale, Ms. Feigal directly holds 12,340 shares. This transaction occurs as Xencor shares have gained 48% over the past year but are considered overvalued by InvestingPro analysis, which also highlights revenue and profitability challenges.
Insider Sell Alert: Ellen Feigal Sells Shares of Xencor Inc (XNC
Ellen Feigal, a Director at Xencor Inc (XNCR), sold 6,843 shares of the company on June 18, 2026. This transaction follows a pattern of 15 insider sells and no buys at Xencor over the past year. With shares trading at $13.06 and a GF Value of $9.62, the stock is considered significantly overvalued per GuruFocus's intrinsic value estimate.
Form 4 Xencor Inc For: 22 June By Investing.com
This article reports on the filing of Form 4 for Xencor Inc. on June 22. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by insiders (officers, directors, or 10% shareholders). The article provides no further details about the specific transactions.
Xencor director Ellen Feigal sells $89,369 in company stock
Xencor Inc. director Ellen Feigal sold 6,843 shares of company stock, valued at $89,369, under a pre-arranged trading plan. This transaction leaves Ms. Feigal with 12,340 direct shares. The sale comes as Xencor's stock has seen a 48% gain over the past year, but InvestingPro analysis suggests the stock is overvalued due to revenue and profitability challenges.
Xencor (XNCR) director’s 10b5-1 sale covers 6,843 common shares
Xencor Inc. (XNCR) director Ellen Feigal reported the sale of 6,843 shares of common stock at $13.06 per share on June 18, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in June 2025. Following this sale, Feigal directly holds 12,340 shares of Xencor stock.
Xencor, Inc. Files 8-K: Company Details, Stock Info, and Executive Plan Updates for 2026
Xencor, Inc. (NASDAQ: XNCR) announced the results of its 2026 Annual Meeting of Stockholders, where all nine nominated directors were re-elected and KPMG LLP was ratified as the independent auditor. A key decision was the approval of an amendment to the 2023 Equity Incentive Plan, authorizing an additional 4,000,000 shares for issuance, which may have a dilutive effect on existing shareholders but aims to attract and retain talent. Shareholders also gave advisory approval to executive compensation, indicating broad confidence in the company's current direction despite potential share dilution.
Xencor (NASDAQ: XNCR) investors back 4M-share equity plan boost and all proposals
Xencor, Inc. stockholders approved all proposals at their 2026 Annual Meeting, including the election of nine directors, the ratification of KPMG LLP as their independent auditor, and an amendment to the 2023 Equity Incentive Plan to increase authorized shares by 4,000,000. Additionally, shareholders gave advisory approval for the compensation of named executive officers. The meeting saw high participation, with over 86% of outstanding shares represented.
Why (XNCR) Price Action Is Critical for Tactical Trading
This article analyzes Xencor Inc. (NASDAQ: XNCR) stock, highlighting a strong "overweight" sentiment across all time horizons. It details institutional trading strategies, including long position, momentum breakout, and short risk-hedging strategies, with specific entry points, targets, and stop losses. The analysis also provides multi-timeframe signal analysis, showing strong support and resistance levels for near, mid, and long-term traders.
Xencor Inc (XNCR) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Xencor Inc's (XNCR) dividend and stock split history. It states that Xencor Inc has distributed $0.00 in dividends over the past five years and reports "No Data" for both dividend payouts and stock splits, indicating the company has not had such events listed. The article presents real-time stock quotes and market capitalization for Xencor Inc.
[144] Xencor Inc SEC Filing
This article announces an SEC Form 144 filing by Xencor Inc. (XNCR), categorized as having a neutral filing impact and sentiment. The filing pertains to the proposed sale of securities under Rule 144, detailing information about the filer, issuer, securities to be sold, and acquisition details. A key detail is the proposed sale of 6843 units of common stock, acquired on June 12, 2026, through restricted stock vesting, with an approximate sale date of June 18, 2026.
Xencor Inc (XNCR) Valuation: PE, PB & Fair Value Analysis
Xencor Inc (XNCR) has a current valuation score of 6.58, placing it 321st out of 388 in the Biotechnology & Medical Research industry. Its P/E ratio is -5.57, which is a significant deviation from both its recent high and low P/E figures. Key valuation metrics like P/E, P/B, P/S, and P/CF ratios have not been fully disclosed by the company yet.
Xencor (Nasdaq:XNCR) - Stock Analysis
This Simply Wall St report provides a detailed analysis of Xencor (XNCR), a clinical-stage biopharmaceutical company focusing on cancer and autoimmune diseases. It highlights Xencor's current valuation, future growth prospects, financial health, and recent news, including positive Phase 1 study results for XmAb942 in inflammatory bowel disease and the planned initiation of a Phase 1 study for XmAb412. The article also covers analyst price targets, insider transactions, and comparisons with competitors.
Director at Xencor (XNCR) sells 7,527 shares under 10b5-1 plan
Xencor director Kevin Charles Gorman sold 7,527 shares of the company's common stock at $12.31 per share through an open-market transaction. This sale was conducted under a pre-established 10b5-1 trading plan adopted on June 27, 2025. Following the transaction, Gorman directly holds 11,378 Xencor shares.
Xencor Inc (XNCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Xencor Inc (XNCR), detailing its business segments. Key revenue streams include Royalties and Milestone payments for the given fiscal year. The company's financial data by business segment is presented with respective proportions.
Xencor (XNCR) director Ranieri sells 5,474 shares under 10b5-1 plan
Xencor Inc. director Richard J. Ranieri sold 5,474 shares of company stock at $12.31 per share on June 15, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. Following this open-market transaction, Ranieri directly holds 13,709 shares of Common Stock. This sale, valued at approximately $67,385, was reported via a Form 4 SEC filing.
Xencor Inc (XNCR) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Xencor Inc (XNCR), listing major institutional holders and their proportional ownership. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent changes in holdings by key investors. Additionally, the article lists related ETFs that hold Xencor shares.
Xencor (XNCR) director sells 5,474 shares under Rule 10b5-1 plan
Xencor director Kurt A. Gustafson reported an open-market sale of 5,474 shares of Common Stock at $12.31 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Gustafson directly holds 14,709 shares of Xencor.
Planned share sale by Xencor (XNCR) director under Rule 10b5-1 plan
Xencor Inc. director Alan Bruce Montgomery reported an open-market sale of 5,064 shares of Xencor common stock at $12.31 per share on June 15, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026, indicating the sale was planned in advance rather than spontaneously decided. Following the sale, Montgomery directly holds 15,547 shares of Xencor common stock.
Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates
Xencor Inc (XNCR) has an earnings forecast score of 8.29, ranking 142nd in its industry. Analysts have set an average price target of $27.00, with a consensus of a "Buy" rating based on 14 analysts. The company's expected revenue for the next quarter is $20.90M, and EPS for the upcoming quarter is projected at -$0.80.
[144] Xencor Inc SEC Filing
Xencor Inc. filed a Form 144 with the SEC on June 15, 2026, indicating a proposed sale of 5,064 shares of common stock with an aggregate market value of $62,337.84. The shares were acquired on June 12, 2026, through restricted stock vesting as compensation from the issuer. This filing highlights an insider's intent to sell securities and details the acquisition method and total shares outstanding.
Xencor Inc Stock (US98401F1057): Analyst Views In Focus After Recent Collaboration Momentum
Xencor Inc. (XNCR) is gaining renewed analyst attention due to recent collaboration milestones in its antibody and cytokine engineering pipeline, shifting its perception from an early-stage biotech to a royalty and platform play. Analysts are focusing on the durability of its royalty streams from approved partner drugs and the visibility of its mid-stage internal programs. The company's strong balance sheet, bolstered by collaboration payments, is also seen as a mitigating factor against financing risks.
Understanding Momentum Shifts in (XNCR)
This article analyzes Xencor Inc. (NASDAQ: XNCR) with a neutral near and mid-term outlook, but a potential long-term positive bias. It highlights a mid-channel oscillation pattern and offers three AI-generated trading strategies tailored for different risk profiles: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy. The analysis also provides multi-timeframe signal analysis, including support and resistance levels, for optimal positioning and risk management.
Xencor Inc stock (US98401F1057): shares react to Monjuvi first-line lymphoma update and recent Q1 20
Xencor Inc.'s shares are under scrutiny following partner Incyte's announcement that Monjuvi, an immunotherapy utilizing Xencor's technology, could become a first-line lymphoma treatment. This update provides a fresh fundamental backdrop for investors, occurring as the company also reported a significant Q1 2026 loss, with EPS of USD -1.71 against a consensus of USD -0.75. The company's business model relies on licensing engineered antibodies and cytokine therapies, making clinical and partnering milestones crucial for its investment phase.
XNCR Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for Xencor Inc (XNCR), indicating an overall "Strong Sell" consensus based on various technical indicators and moving averages. Key metrics like MACD and several moving averages suggest a bearish outlook, though some short-term moving averages show a "Buy" signal. The analysis also details support and resistance levels, and momentum indicators like RSI and Stochastic Oscillator.
Xencor Inc stock (US98401F1057): shares trade around recent lows as investors digest pipeline and va
Xencor Inc. shares on Nasdaq are trading near their recent lows as investors weigh the company's antibody engineering pipeline and balance sheet against broader biotech market sentiment. The stock's valuation is sensitive to trial milestones, licensing deals, and funding, reflecting the inherent risks and opportunities of a clinical-stage biopharmaceutical company. Market analysts currently hold a "Hold" rating, indicating a balance between potential catalysts and development uncertainties.
Avoiding Lag: Real-Time Signals in (XNCR) Movement
The article analyzes Xencor Inc. (NASDAQ: XNCR) using AI models, identifying a mid-channel oscillation pattern with an exceptional 101.0:1 risk-reward setup targeting a 27.5% gain. It provides three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles and holding periods, alongside multi-timeframe signal analysis.
Jefferies Financial Group Inc. Purchases 620,440 Shares of Xencor, Inc. $XNCR
Jefferies Financial Group Inc. significantly increased its stake in Xencor, Inc. by purchasing 620,440 shares in the fourth quarter, bringing its total holdings to 720,440 shares valued at approximately $11.0 million. This move comes amid mixed analyst sentiment, with the stock holding an average "Hold" rating and a consensus target price of $24.50. Meanwhile, insiders have been selling shares, with total insider sales reaching 44,020 shares over the last 90 days.
T-cell Engagers Market to Record US$ 58.04 billion by 2035.
The global T-cell Engagers Market is projected to reach US$ 58.04 billion by 2035, growing at a CAGR of 22.73% from its 2025 valuation of US$ 7.27 billion. Key industry developments include advancements in BiTE platforms, expansion of manufacturing capabilities, and strategic collaborations among major pharmaceutical companies like Amgen, Johnson & Johnson, and Regeneron. The market's growth is driven by increasing adoption, investments, and innovations in oncology immunotherapy and autoimmune disease treatments across various regions.
Xencor Inc stock (US98401F1057): JPMorgan lifts target while investors eye Q1 2026 update
JPMorgan Chase & Co. has raised its price target for Xencor Inc. to $14 per share, following the biotech company's release of its first-quarter 2026 financial results. Xencor, a clinical-stage biopharmaceutical company focused on antibody and protein therapeutics, relies on collaboration revenues, milestone payments, and royalties from partners, while also developing its own oncology and autoimmune candidates. The stock experienced volatility, closing at $11.22 on May 15, 2026, highlighting the sensitivity of development-stage biotechs to news flow and clinical progress.
Xencor, Inc. $XNCR Shares Sold by UBS Group AG
UBS Group AG significantly reduced its holdings in Xencor, Inc. (NASDAQ:XNCR) by 45.7% in the fourth quarter, selling over 537,000 shares. This comes as Xencor reported a substantial miss on earnings estimates and an 86.2% year-over-year revenue decrease. Analyst sentiment for Xencor is mixed but leaning cautious, with recent downgrades counteracted by some higher price targets, resulting in a current "Hold" average rating.
EcoR1 reports 2.9% Xencor stake (NASDAQ: XNCR)
EcoR1 Capital, LLC, along with related filers, has reported a beneficial ownership of 2.9% in Xencor Inc. (NASDAQ: XNCR), totaling 2,183,000 shares. A separate entity, EcoR1 Capital Fund Qualified, L.P., holds 2.8%, or 2,041,033 shares. These percentages are calculated based on 71,141,596 shares outstanding as of May 1, 2026, and the filing clarifies that these stakes do not intend to change, or influence control of, Xencor.
Xencor stock (US98401F1057): Biotech focus on immunotherapy and protein engineering
Xencor Inc. (XNCR) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy candidates for cancer treatment using proprietary protein engineering technology. The company's business model relies on advancing its pipeline through clinical development and securing regulatory approvals, with revenue expected from commercialization and partnerships. Investors are advised to monitor clinical trial progress, partnership announcements, and capital management as key indicators for this volatile stock in the competitive immunotherapy market.
Xencor stock (US98401F1057): Biotech innovator in antibody therapies
Xencor Inc. (XNCR) is a biotechnology company specializing in developing bispecific antibodies and protein therapeutics for cancer and autoimmune diseases, leveraging its proprietary XmAb platform. The company's business model relies on internal pipeline development and strategic partnerships with major pharmaceutical firms, generating revenue through upfront payments, milestones, and royalties. Xencor continues to advance its clinical programs, targeting unmet medical needs and offering investors exposure to innovation in the evolving immunotherapy landscape.
Xencor Is Maintained at Neutral by JP Morgan
JP Morgan has maintained its Neutral rating on Xencor. The article does not provide further details regarding the rationale behind this rating or any financial analysis.
Xencor (NASDAQ:XNCR) Price Target Raised to $14.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. has raised its price target for Xencor (NASDAQ:XNCR) to $14.00 from $13.00, maintaining a "neutral" rating on the biopharmaceutical stock despite previous weak quarterly results. The new target suggests a potential upside of 9.25% from the current share price. Analyst opinions on Xencor are mixed, with an average "Hold" rating and a consensus price target of $24.50 across various firms.
These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts
Analysts have significantly downgraded their near-term forecasts for Xencor, Inc. (NASDAQ:XNCR), anticipating a substantial decline in revenue and increased losses per share for 2026. This pessimistic outlook suggests a clear change in sentiment towards the biopharmaceutical company, whose revenues have already been declining over the past five years. Despite the downgrades, the consensus price target remains unchanged, though the worsening business conditions could impact the stock price.
Xencor (NASDAQ:XNCR) Rating Lowered to Strong Sell at Wall Street Zen
Xencor (NASDAQ:XNCR) has been downgraded to a "Strong Sell" rating by Wall Street Zen, adding to a mixed analyst outlook that includes a consensus "Hold" rating and a target price of $24.38. This downgrade follows the company's significantly worse-than-expected quarterly loss of ($1.71) EPS against an anticipated ($0.75), and revenue of $4.52 million, which fell well below estimates and represented an 86.2% year-over-year decline. The article also notes continued insider selling despite a recent 4.5% stock price increase, with analysts expecting a full-year loss for Xencor.
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
Xencor, Inc. announced final results from its Phase 1 study of XmAb942, an anti-TL1A antibody for inflammatory bowel disease, which support its potential as a best-in-class treatment. The company also presented preclinical data for XmAb412, a novel bispecific antibody, and plans a first-in-human study for Q3 2026. Xencor will host a webcast on May 5th to discuss these data presentations and their implications for the treatment of autoimmune and inflammatory diseases.
